Buy GRAL by Mar 23, 2026.

$GRAL is a pure play on early cancer detection, with its Galleri blood test targeting a problem the healthcare system has never solved well: catching multiple cancers before symptoms appear. Galleri can screen for dozens of cancers in a single blood draw, many of which currently have no routine screening, and that alone puts it in a category with massive long term upside if adoption scales. The addressable market is enormous, and success here is less about quarterly numbers and …